Citations

Clear

4207 citation(s) found for "Chen, Yu".

Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis
Zhang, Ting , Mohindroo, Chirayu , Wang, Xiaoyu , Dutta, Diptavo , Liu, Jia , Katta, Shilpa, Li, Shengchao A. , Wang, Jiahui , Antwi, Samuel O. , Bracci, Paige M. , Du, Mengmeng, Gallinger, Steven , Goodman, Phyllis J. , Katzke, Verena, Patel, Alpa V. , Visvanathan, Kala , Andreotti, Gabriella , Brennan, Paul , Buring, Julie E. , Chanock, Stephen J., Chen, Yu , Giovannucci, Edward L. , Haiman, Christopher A. , Hassan, Manal M. , Holly, Elizabeth A., Jones, Miranda R. , Kraft, Peter, Kurtz, Robert C. , Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Rabe, Kari G. , Rothman, Nathaniel , Sesso, Howard D. , Yuan, Chen, Wolpin, Brian M. , Yu, Kai , Stolzenberg‐Solomon, Rachael Z. , Mohindroo, Chirayu , Wang, Xiaoyu , Dutta, Diptavo , Liu, Jia , Li, Shengchao A , Antwi, Samuel O , Arslan, Alan A , Beane Freeman, Laura E , Canzian, Federico , Du, Mengmeng , Goodman, Phyllis J , Katzke, Verena , Kooperberg, Charles , Marchand, Loïc Le , Neale, Rachel E , Perdomo, Sandra , Shu, Xiao-Ou , Visvanathan, Kala , Van Den Eeden, Stephen K , White, Emily E. , Zheng, Wei , Albanes, Demetrius , Andreotti, Gabriella , Brennan, Paul , Buring, Julie E , Chanock, Stephen Jacob , Chen, Yu , Darst, Burcu F , Ferrari, Pietro , Giovannucci, Edward L , Goggins, Michael G , Haiman, Christopher A , Hassan, Manal M , Hung, Rayjean J , Jones, Miranda R , Kraft, Peter , Malats, Nuria , Moore, Steven C , Ng, Kimmie , Oberg, Ann L , Orlow, Irene , Peters, Ulrike , Porta, Miquel , Chaffee, Kari G. , Sánchez, Maria-Jose , Sesso, Howard D , Southey, Melissa C , Um, Caroline Y , Yarmolinsky, James , Yu, Herbert , Yuan, Chen , Zhong, Jun , Wolpin, Brian M , Risch, Harvey A , Amundadottir, Laufey , Klein, Alison P , Yu, Kai , Zhang, Haoyu , Stolzenberg-Solomon, Rachael , Zhang, Ting , Hua, Xing , Arslan, Alan A. , Freeman, Laura E. Beane , Canzian, Federico , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Darst, Burcu F. , Goggins, Michael , Hung, Rayjean J. , Malats, Núria , Moore, Steven C. , Orlow, Irene , Porta, Miquel , Sánchez, María‐José , Silverman, Debra T. , Southey, Melissa C. , Um, Caroline Y. , Yu, Kai , Risch, Harvey A. , Ámundadóttir, Laufey T. , Klein, Alison P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 8, 2025 | Volume: 118 | Issue: 3 | Pages: 437-447

10.1093/jnci/djaf308 | PMID 41206949 Get It

Abstract Background The associations between different types of diabetes, characterized by distinct pathophysiology and genetic architecture, and pancreatic ductal adenocarcinoma (PDAC) risk are not understood. Methods We investigated associations of genetic susceptibility to type 2 diabetes (T2D), 8 T2D mechanistic clusters, type 1 diabetes (T1D), and maturity-onset diabetes of the young (MODY) with PDAC risk. We used genome-wide association study (GWAS) summary-level statistics for T2D (242 283 cases, 1 569 734 controls), T1D (18 942 cases, 501 638 controls), and PDAC (10 244 cases and 360 535 controls) in individuals of European ancestry. Results Two-sample Mendelian randomization (MR) using the Robust Adjusted Profile Score (MR-RAPS) method indicated that genetically predicted T2D was associated with PDAC risk (OR = 1.10; 95% CI = 1.05 to 1.15), particularly the T2D obesity (OR = 1.28; 95% CI = 1.15 to 1.42) and lipodystrophy (OR = 1.25; 95% CI = 1.03 to 1.51) clusters. No association was observed for T1D with PDAC risk (OR = 1.01; 95% CI = 0.99 to 1.02). Pathway/gene-set analysis using the summary-based Adaptive Rank Truncated Product (sARTP) method revealed a significant association between the MODY gene-sets and PDAC risk (P = 1.5 × 10−8), which remained after excluding 20 known PDAC GWAS loci (P = 7.6 × 10−4). HNF1A, FOXA3, and HNF4A were the top contributing genes after excluding the previously identified GWAS loci regions. Conclusions Our results from this genetic association study support that T2D, particularly the obesity and lipodystrophy mechanistic clusters, and MODY genomic susceptibility regions play a role in the etiology of PDAC.
Pathogenic PF4/Polyvinylsulfonate ELISA-negative Antibodies in HIT
Kanack, Adam J. , Splinter, Noah P., Mauch, Emily, Gil, Morayma Reyes , Jasra, Sakshi , Goodwin, Andrew , Smock, Kristi J. , Ahmad, Hadiyah, Ashrani, Aneel A. , Robinson, Nathaniel L. , Jones, Curtis G., Pechauer, Shannon M., yttre, erin , Aster, Richard H. , Kohlhagen, Mindy , Leger, Rachel, Murray, David, Zhou, Lu , Wang, Demin , Wen, Renren , Pruthi, Rajiv K. , Padmanabhan, Anand , Mauch, Emily E, Tefera, Leben, Kohlhagen, Mindy C, Leger, Rachel R, Wang, Demin , Tefera, Leben T. , Ahmad, Hadiyah, Casanegra, Ana I. , Jones, Curtis G., Chen, Dong

Mayo Clinic

No container title available | November 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.10.29.25338884 | PMID 41282766 Get It

ABSTRACT BACKGROUND Platelet factor 4-polyanion enzyme-linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin-induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA-negative results to exclude HIT. Once HIT is ruled out, alternative, non-heparin-based anticoagulant treatments are ceased, and heparin reintroduction frequently occurs. METHODS Antigen-based and PF4-dependent functional testing were used to study PF4/polyvinyl sulfonate ELISA-negative platelet-activating antibodies in HIT-suspected patients and mice immunized with PF4/heparin. RESULTS Three patients with clinical presentations consistent with HIT tested negative in an ELISA using PF4-polyvinylsulfonate (PF4/PVS), an antigenic target very commonly used for HIT antibody detection. All three patients demonstrated PF4-dependent platelet activation in functional testing that was sensitive to blockade of platelet FcγRIIa receptors and inhibited by high concentrations of heparin, consistent with pathogenic HIT antibodies. Functional testing-based screening of 500 ELISA-negative patients identified three patients whose sera activated platelets in a PF4- and FcγRIIa-dependent manner, and had clinical histories consistent with HIT. Five of the six ELISA-negative HIT patients were re-exposed to heparin, which precipitated a decrease in platelet counts in all re-exposed patients, and one patient developed a new thrombus. To advance the study of ELISA-negative HIT antibodies, mice were immunized with PF4/heparin, and functional and antigenic assays were simultaneously used to successfully identify an ELISA-negative, PF4-dependent platelet-activating murine monoclonal antibody that recapitulated the serological characteristics of ELISA-negative HIT patients. CONCLUSIONS Recognition of ELISA-negative HIT is critical to avoid harm due to the cessation of alternative anticoagulation therapy and re-exposure of these patients to heparin.
Shape analysis of the amygdala, hippocampus and thalamus in former American football players
John, Omar , Wickham, Alana, Jung, Leonard , Mirmajlesi, Anya S, Stearns, J. W. , Breedlove, Katherine M. , Billah, Tashrif , Pasternak, Ofer , Chamaria, Arushi , Bernick, Charles , Balcer, Laura J. , Rushmore, R. Jarrett , Alosco, Michael L. , Lin, Alexander , Cummings, Jeffrey L., Reiman, Eric M. , Arciniega, Hector , Su, Yi, Chen, Kewei, Protas, Hillary, Boker, Connie, Alosco, Michael L, Au, Rhoda, Cantu, Robert C, Farrer, Lindsay, Helm, Robert, Katz, Douglas I, Kowall, Neil, Mez, Jesse, Mercier, Gustavo, Otis, James, Weller, Jason, Simkin, Irene, Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Rice, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Pasternak, Ofer, Arcinieago, Hector, Coello, Eduardo , Coleman, Michael J. , Jung, Leonhard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Marmar, Charles R. , Hasanaj, Lisena, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard M., Johnson, Keith A, Jung, Leonard B , Stearns, Jared , Breedlove, Katherine , Tripodis, Yorghos , Adler, C H , Alosco, Michael L , Koerte, Inga K , Arciniega, Hector , Kim, Nicholas , Daneshvar, Daniel H. , Coleman, Michael , Tripodis, Yorghos , Adler, Charles H. , Stern, Robert A. , Shenton, Martha E. , Bouix, Sylvain , Su, Yi, Chen, Kewei, Alosco, Michael L., Au, Rhoda, Cantu, Robert C. , Mez, Jesse, Weller, Jason , Simkin, Irene, Fagle, Tessa, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Wiegand, Tim L. T. , Miller, Jason Rafe , Sabbagh, Marwan Noel , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Bellgowan, Patrick S.F. , Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Kirov, Ivan I. , Lui, Yvonne W. , George, Allan, Riley, Edward P. , Cummings, Jeffrey L. , Johnson, Keith A.

Mayo Clinic

Brain Communications | November 6, 2025 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/braincomms/fcaf440 | PMID 41277896 Get It

Abstract Repetitive head impacts are common in contact and collision sports and are linked to structural brain changes and an elevated risk of neurodegenerative diseases such as Chronic Traumatic Encephalopathy. Identifying early in vivo structural markers remains challenging. Although diagnosis currently requires post-mortem confirmation, clinical symptoms, including cognitive impairment and behavioural changes, are reflected in the diagnosis of Traumatic Encephalopathy Syndrome. These symptoms align with dysfunction in key brain regions—amygdala, hippocampus and thalamus—which support memory, emotion and behaviour and commonly show tau pathology in Chronic Traumatic Encephalopathy. This study uses shape analysis to examine structural differences in these regions between former American football players and unexposed asymptomatic controls and evaluates the influence of age, head impact exposure and clinical diagnosis on brain structure. We analyzed brain morphology in former American football players (n = 163) and unexposed, asymptomatic controls (n = 53). Structural segmentation was performed with FreeSurfer 7.1, and the shape analysis pipeline was used to generate subregional reconstructions. Vertex-level morphometry, based on the logarithm of the Jacobian determinant and radial distance, quantified local surface area dilation and thickness. Group differences were examined with covariate-adjusted linear regression models contrasting football players and controls, as well as participants with and without a Traumatic Encephalopathy Syndrome diagnosis. Partial correlations examined the influence of age, age of first football exposure and cumulative head impact index metrics, including frequency, linear acceleration and rotational force. Models were adjusted accordingly for age, body mass index, education, race, imaging site, apolipoprotein ϵ4 status and total intracranial volume. Former football players exhibited bilateral surface area contractions in the hippocampus and amygdala, along with reduced amygdala thickness, compared to controls. Older age was associated with widespread surface contractions and thinning across all regions, except for preserved thickness in the left hippocampus. An earlier age of first exposure to football correlated with surface contractions in the thalamus and left hippocampus. Greater cumulative linear acceleration was linked to bilateral hippocampal surface contractions and reduced thickness in the left thalamus, while greater rotational force exposure was associated with hippocampal thinning. No significant structural differences were found between players with and without a diagnosis of Traumatic Encephalopathy Syndrome. These findings extend volume-based research by revealing localized alterations in surface area dilation and thickness and emphasize the roles of age and repetitive head impact exposure in long-term brain changes.
Semaglutide and diabetic retinopathy: an OHDSI network study
Cai, Cindy X. , Hribar, Michelle R. , Wang, Sophia Y. , Swaminathan, Swarup S. , Flowers, Alexis , Brown, Eric N. , Chen, John J. , Chen, Aiyin , Alshammari, Thamir , Falconer, Thomas , Martin, Benjamin , Westlund, Erik , Mathioudakis, Nestoras , Fan, Ruochong, Stocking, Jacqueline C. , Humes, Izabelle, McCoy, David , Adibuzzaman, Mohammad, Areaux, Raymond G. , Brash, James T., Morgan‐Cooper, Hannah, Desai, Priya , Rustam, Zainab, Zhu, Gu , Swerdel, Joel N. , Suchard, Marc A. , Ryan, Patrick , Cai, Cindy Xinji , Barkmeier, Andrew, Stocking, Jacqueline C , Chen, John J , Mathioudakis, Nestoras N , Nishimura, Akihiko, Baxter, Sally L. , Goetz, Kerry , Toy, Brian C. , Barkmeier, Andrew J. , Xu, Benjamin Yixing , Leng, Theodore , Boland, Michael V. , Bu, Fan , Martin, Benjamin, Zhang, Linying , Fan, Ruochong, Wilcox, Adam B , Lai, Albert M. , Xie, Yangyiran , Lee, Lok Hin , Dorr, David A , Weiskopf, Nicole G. , Desai, Priya, Tran, Diep D. , Rustam, Zainab, Sena, Anthony G. , Nagy, Paul G. , Schuemie, Martijn J. , Hripcsak, George

Mayo Clinic

BMJ Open Diabetes Research & Care | November 5, 2025 | Volume: 13 | Issue: 6 | Pages: e005424

10.1136/bmjdrc-2025-005424 | PMID 41192935 Get It

Introduction Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes mellitus (T2D), has potential associations with higher rates of diabetic retinopathy (DR) complications including proliferative DR (PDR) and diabetic macular edema (DME). The purpose of this study was to determine whether an association exists between semaglutide and PDR and treatment-requiring DR/DME. Research design and methods This was a retrospective cohort study of 14 databases (six administrative claims and eight electronic health records) in the Observational Health Data Sciences and Informatics Evidence Network. Adults with T2D on semaglutide, other GLP-1RA (dulaglutide, exenatide), or non-GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from 1 December 2017 to 31 December 2023 were included. The association between semaglutide and PDR or treatment-requiring DR/DME was assessed using an active-comparator cohort design comparing new users of semaglutide as second-line T2D treatment to those on other GLP-1RAs and non-GLP-1RAs. Propensity score-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs). Network-wide HR estimates were generated using a random-effects meta-analysis. Results The study included 810 390 new semaglutide users for T2D. PDR risk for semaglutide was similar to dulaglutide (HR 0.81, 95% CI 0.42 to 1.54, p=0.51), empagliflozin (HR 0.83, 95% CI 0.53 to 1.30, p=0.41) and sitagliptin (HR 0.83, 95% CI 0.45 to 1.55, p=0.57) but was lower than glipizide (HR 0.59, 95% CI 0.39 to 0.88, p=0.01). The risk for treatment-requiring DR/DME for semaglutide was similar to empagliflozin (HR 0.66, 95% CI 0.43 to 1.02, p=0.06) but lower than dulaglutide (HR 0.53, 95% CI 0.31 to 0.91, p=0.02), sitagliptin (HR 0.46, 95% CI 0.26 to 0.81, p=0.008) and glipizide (HR 0.55, 95% CI 0.33 to 0.91, p=0.02). Conclusions and relevance We did not identify increased risk for either PDR or treatment-requiring DR/DME comparing semaglutide with other GLP-1RAs or non-GLP-1RAs. Patients with T2D should still undergo close eye care follow-up, particularly when initiating new antihyperglycemic medications.
603 SUPRAME: a phase 3 trial evaluating IMA203 PRAME-directed TCR T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma
Moser, Justin, Amaria, Rodabe N, Warner, Allison Betof, Chmielowski, Bartosz, Fecher, Leslie A, Chandrasekaran, Sanjay, Chen, Ruqin, Cowey, Charles L, Daniels, Gregory A, Daud, Adil, Dimitrova, Maya, Dudek, Arkadiusz Z, Haugh, Alexandra, Hernandez-Aya, Leonel, Hu-Lieskovan, Siwen, Hurwitz, Michael E, Isaacs, James M, Karapetyan, Lilit, Lee, Sylvia, Mammen, Joshua MV, Mckean, Meredith, Mitchell, Tara C, Moschos, Stergios J, Naqash, Abdul Rafeh, Olson, Daniel J, Olszanski, Anthony J, Patel, Sapna P, Poklepovic, Andrew S, Robert, Caroline, Schadendorf, Dirk, Seedor, Rino S, Seetharam, Mahesh, Smithy, James W, Solomon, Benjamin M, Taylor, Matthew H, Terhune, Julia H, Viray, Hollis A, Whitman, Eric D, Wu, Richard, Xing, Yan, Krishna, Delfi, Mayer-Mokler, Andrea, Pankov, Dmitry, Britten, Cedrik M, Luke, Jason J, Moser, Justin, Amaria, Rodabe N, Warner, Allison Betof, Chmielowski, Bartosz, Fecher, Leslie A, Chandrasekaran, Sanjay, Chen, Ruqin, Cowey, Charles L, Daniels, Gregory A, Daud, Adil, Dimitrova, Maya, Dudek, Arkadiusz Z, Haugh, Alexandra, Hernandez-Aya, Leonel, Hu-Lieskovan, Siwen, Hurwitz, Michael E, Isaacs, James M, Karapetyan, Lilit, Lee, Sylvia, Mammen, Joshua MV, Mckean, Meredith, Mitchell, Tara C, Moschos, Stergios J, Naqash, Abdul Rafeh, Olson, Daniel J, Olszanski, Anthony J, Patel, Sapna P, Poklepovic, Andrew S, Robert, Caroline , Schadendorf, Dirk, Seedor, Rino S, Seetharam, Mahesh, Smithy, James W, Solomon, Benjamin M, Taylor, Matthew H, Terhune, Julia H, Viray, Hollis A, Whitman, Eric D, Wu, Richard, Xing, Yan, Krishna, Delfi, Mayer-Mokler, Andrea, Pankov, Dmitry, Britten, Cedrik M, Luke, Jason J

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A687-A687

10.1136/jitc-2025-sitc2025.0603 Get It

844 Immune cell profile changes in patients treated with tarlatamab for extensive-stage small cell lung cancer in real world practice
Ma, Audrey, Corraes, Andre De Menezes Silva , Wu, Chen , Shao, Zuoyi , Regan, Kevin M., Karam, Dhauna , Potter, Ashley , Al‐Ajmi, Abdullah, Mina, Syeda A. , Taylor, Skyler, Parikh, Kaushal , Shanshal, Mohamed , Luce, A., Schwecke, Anna, Lin, Yi , Leventakos, Konstantinos , Taylor, Skyler J, Hazim, Antonious , Dimou, Anastasios , Molina, Julian, Mansfield, Aaron S. , Smith, Katherine E.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A953-A954

10.1136/jitc-2025-sitc2025.0844 Get It

281 T cell metabolic pathway enrichment profiles associated with clinical response in CD19 CAR-T therapy for aggressive B-cell non-Hodgkin’s lymphoma
Tan, Melinda Si Yun , Wang, Panwen , Corraes, Andre De Menezes Silva , Wu, Chen , Shao, Zuoyi , Regan, Kevin M., Ma, Audrey, Khurana, Arushi , Bennani, Nabila N, Hampel, Paul J. , Johnston, Patrick B. , Ansell, Stephen M. , Bennani, Nabila N, Wang, Yucai , Paludo, Jonas , Durani, Urshila , Villasboas, José C. , Mondello, Patrizia , Zeng, Hu , Dong, Haidong , Li, Ying , Lin, Yi

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A314-A314

10.1136/jitc-2025-sitc2025.0281 Get It

AASLD IDSA Practice Guideline on treatment of chronic hepatitis B
Ghany, Marc G. , Frick, Andrew , Lok, Anna S. , Feld, Jordan J. , Lim, Joseph K. , Wang, Su H. , Kim, A Y, Tang, Amy S. , Nguyen, Mindie H. , Naggie, Susanna, Sulkowski, Mark S. , Rodriguez‐Baez, Norberto, Chen, Jacki, Mohammad, Khaled S. , Kim, Arthur Y. , Naggie, Susanna , Pan, Calvin Q , Kim, Arthur Y , Naggie, Susanna , Murad, M Hassan , Mohammad, Khaled S , Terrault, Norah , Nguyen, Mindie H , Chen, Jacki, Terrault, Norah A.

Mayo Clinic

Hepatology | November 4, 2025 | Volume: 83 | Issue: 4 | Pages: 974-997

10.1097/hep.0000000000001549 | PMID 41186418 Get It

Background and Aims: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Methods: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline. Conclusions: This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
Burden of Central Nervous System Cancer in the United States, 1990-2021
Collaborators, GBD 2021 US CNS Cancer, Han, Hyun Jin , Kim, Yun Seo , Park, Seoyeon , Shin, Jae Il , Kim, Min Seo , Areda, Demelash, Tork, Mohammad Amin Bayat , Bilgin, Gokce Belge , Chennapragada, Suma Sri , Dean, Frances , Deekonda, Sindhura, Ding, Xueting, E’mar, Abdel Rahman, Elhadi, Muhammed, Fazeli, Patrick , Fisher, James L. , Fotouhi, Maryam , Gholamrezanezhad, Ali , Ida, Fidelia , Jani, Chinmay , Kalani, Rizwan , Kazemi, Foad , Keshwani, Ariz, Khosla, Atulya Aman , Lim, Stephen S , Murray, Christopher J L , Naik, Gurudatta , Nguyen, Dang Tuan , Penberthy, Louise, Pestell, Richard G. , Prabhu, Disha , Ramasamy, Shakthi Kumaran, Sabet, Cameron John, Şenol, Yiğit Can , Sham, Sunder, Solanki, Ranjan , Tanwar, Manoj , Amirikah, Mike Tuffour, Verma, Anjul, Yon, Dong Keon, Yon, Dong Keon , Shin, Jae I L , Senol, Yigit Can , Collaborators, GBD 2021 US CNS Cancer, Moon, Ju Hyung , Kim, Yong Bae , Ababneh, Hazim , Abu‐Zaid, Ahmed , Arul, Santhosh , Azzam, Ahmed Y , Bardhan, Mainak , Behnam, Babak , Bhardwaj, Prarthna V , Bhuyan, Soumitra Sudip , Lomer, Nima Broomand , Chen, Mengxuan , Dai, Xiaochen , Doshi, Ojas Prakashbhai , Fares, Jawad , Iwu, Chidozie Declan , Jalloh, Mohamed, Kankam, Samuel Berchi , Mehboob, Riffat , Meštrović, Tomislav , Mokdad, Ali H. , Natto, Zuhair S. , Nguyen, Dang, Nugen, Fred , Orscelik, Atakan , Parikh, Romil R , Puvvula, Jagadeesh , Ramasamy, Shakthi Kumaran, Sabet, Cameron John , Schumacher, Austin E , Sherchan, Samendra , Simegn, Gizeaddis Lamesgin , Singh, Jasvinder A. , Srichawla, Bahadar Singh , Taiba, Jabeen , Yunusa, Ismaeel , Zheng, David X. , Park, Keun Young

Mayo Clinic

JAMA Neurology | November 3, 2025 | Volume: 83 | Issue: 1 | Pages: 35

10.1001/jamaneurol.2025.4286 | PMID 41182787 Get It

Importance Primary brain and central nervous system cancer (collectively referred to as CNS cancer) comprises 2% of all human cancers and poses significant health and economic challenges in the United States. Objective To analyze CNS cancer burden in the US, stratified by time, location (state and division), sex, age group, and Sociodemographic Index (SDI). Design, Setting, and Participants This cross-sectional study involved a repeated analysis of Global Burden of Disease Study (GBD) 2021 data in 2024. Using data from 183 sources, CNS cancer metrics in the US were estimated across states and years. US CNS cancer metrics across all sexes and age groups were included in the GBD. Exposure CNS cancer diagnosis. Main Outcomes and Measures Overall and age-standardized estimates of the incidence, prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost, and years lived with disability per 100 000 population, including 95% uncertainty intervals (UIs), and time trends. Results In 2021, for all age groups and sexes across the US, there were 31 780 incident cases (95% UI, 29971.1 to 32843.9). Age-standardized incidence, DALYs, and mortality rates per 100 000 population were 6.91 (95% UI, 6.58 to 7.12), 134.38 (95% UI, 129.83 to 137.95), and 4.1 (95% UI, 3.87 to 4.22), respectively. Despite no significant change observed in the overall incidence between 1990 and 2021, DALY and mortality rates decreased by 15.77% (95% UI, −17.75% to −13.68%) and 8.41% (95% UI, −11.09% to −6.22%), respectively. Substantial geographic variability was noted. Mississippi, Alabama, Kentucky, and Kansas (West North Central and East South Central divisions) and West Virginia faced persistently high burdens over the past 30 years. Sex differences were evident; disease burden was consistently higher in males compared with females. Age-specific estimates showed a bimodal distribution: the youngest group (<5 years) showed a significant decrease in incidence rate (−34.42% to −11.56%), whereas older age groups (>70 years) experienced increasing trends. DALYs and mortality rates were negatively correlated with SDI (ρ = −0.6860 and ρ = −0.6391; P < .001). Conclusions and Relevance These findings provide valuable insights into the CNS cancer burden across the US by age, sex, location, and SDI, enabling better public health status assessments, health care policy restructuring, and resource redistribution for improved care.
Abstract 4363872: Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients With Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Sperry, Brett W. , Masri, Ahmad , Grogan, Martha , Mooney, Deirdre, Akinboboye, Olakunle O., Drachman, Brian, Nativi-Nicolau, José , Tamby, Jean‐François, Castaño, Adam , Fox, Jonathan C. , Cheng, Richard K. , Cheng, Richard , Sperry, Brett W , Kobayashi, Masatake , Chen, Christopher S. , Cheng, Richard , Judge, Daniel P. , Cappelli, Francesco

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4363872 Get It

Background: Atrial fibrillation (AF) significantly impacts quality of life (QoL) and is often observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis achieves near-complete (≥90%) transthyretin (TTR) stabilization and is approved in the USA, the UK, Europe and Japan for the treatment of ATTR-CM in adults. In the phase 3 ATTRibute-CM study (NCT03860935), acoramidis treatment significantly reduced the time to all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH) at Month 30, and resulted in improved 6-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) scores and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels relative to placebo. The clinical efficacy of acoramidis has not yet been reported in patients with ATTR-CM and with an AF or atrial flutter (AFL) diagnosis at baseline. Research Question: How does acoramidis treatment affect ACM or first CVH, 6MWD, KCCQ-OS scores, and NT-proBNP levels at Month 30 in participants with ATTR-CM with or without AF/AFL diagnosis at baseline? Methods: The ATTRibute-CM study design has been previously published. This post hoc analysis included participants in the modified intention-to-treat population (N=611) grouped by AF/AFL diagnosis at baseline (defined as recorded AF medical history or the presence of AF or AFL on an ECG at enrollment). The rate of ACM or first CVH at Month 30 was compared between groups using a stratified Cox proportional hazards model. Changes from baseline to Month 30 in 6MWD, KCCQ-OS scores and NT-proBNP levels were summarized descriptively. Results: Overall, 62.8% (384/611) of participants had an AF/AFL diagnosis at baseline (acoramidis: 255/409, placebo: 129/202). These participants had lower mean 6MWD and KCCQ-OS scores and higher median NT-proBNP levels than those without AF/AFL diagnosis at baseline. Treatment with acoramidis reduced ACM or first CVH, slowed the decline in 6MWD and KCCQ-OS scores and blunted the rise in NT-proBNP compared with placebo, regardless of AF/AFL diagnosis at baseline ( Table ). Conclusions: Acoramidis improved clinical outcomes (ACM, CVH), functional status, QoL and NT-proBNP levels relative to placebo in participants with ATTR-CM, regardless of AF/AFL diagnosis at baseline.